Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
BMC Anesthesiol ; 21(1): 102, 2021 04 05.
Artículo en Inglés | MEDLINE | ID: mdl-33820534

RESUMEN

BACKGROUND: Laryngeal mask airways (LMA) are commonly used for airway management. Complications with this device are rare. However, when they do occur, there is a high risk for respiratory problems, necessitating early diagnosis and treatment. We present the first case of a life-threatening abscess spreading in the visceral space caused by a penicillin and metronidazole resistant Prevotella Denticola after the use of an LMA. CASE PRESENTATION: A female patient was admitted to our day care centre for bunion surgery. A single use LMA size 3 (Solus®, intersurgical, Wokingham, Berkshire, United Kingdom) was successfully inserted. After surgery, the patient complained of a sore throat and amoxicillin was prescribed by the general practitioner. Three days after surgery the patient was admitted to the Intensive Care Unit (ICU) for obstructive breathing, due to an abscess in the visceral space. Retropharyngeal and certainly parapharyngeal abscesses in adults are already rare. This case however, is unique because it is the first case of abscess spreading into the visceral space after the use of an LMA. Amoxicillin/clavulanate and vancomycin were started. The abscess was incised 5 days later and microbiology showed 3 positive cultures of the anaerobe Prevotella denticola, resistant for penicillin and metronidazole, but sensitive for amoxicillin/clavulanate. The patient fully recovered. CONCLUSION: LMA's are easy to use and are established, safe tools to support ventilation of the airway. In this case, the authors hypothesise a small wound in the lateral pharyngeal wall probably created an opening into the visceral space causing infection with Prevotella denticola, supporting the idea that the pharyngeal mucosal space must be part of the visceral space. Additionally, early recognition and treatment of an LMA induced abscess is necessary to prevent evolution of complications leading to airway obstruction.


Asunto(s)
Absceso/microbiología , Infecciones por Bacteroidaceae/tratamiento farmacológico , Máscaras Laríngeas/efectos adversos , Absceso/tratamiento farmacológico , Combinación Amoxicilina-Clavulanato de Potasio/uso terapéutico , Antibacterianos/uso terapéutico , Farmacorresistencia Bacteriana Múltiple , Femenino , Humanos , Persona de Mediana Edad , Prevotella , Vancomicina/uso terapéutico
2.
Undersea Hyperb Med ; 46(5): 625-632, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-31683360

RESUMEN

OBJECTIVE: To evaluate the efficiency of percutaneous patent foramen ovale (PFO) closure on the recurrence of decompression illness (DCI). DESIGN: Retrospective, observational study with interview and questionnaire. SETTING: Tertiary referral center. POPULATION: 59 scuba divers with a history of DCI who received a percutaneous PFO closure. MAIN OUTCOME MEASUREMENTS: Questionnaire about health status, dive habits and recurrence of DCI after PFO closure. RESULTS: A total of 59 divers with DCI were included. The most common manifestations of DCI were cutaneous or vestibular DCI. Procedural complications occurred in four patients but none with long-term consequences. Four patients had recurrence of DCI after closure during a 10-year follow-up. In three of these cases there was residual shunting, all of which were initially considered closed. The fourth patient had aggravating factors for his recurrent DCI. A quarter of the patients stated to have changed their diving habits. Four patients quit diving. CONCLUSION: Percutaneous PFO closure for secondary prevention of DCI is associated with few, but not negligible, complications. As a large portion of our cohort changed their diving habit after closure it is difficult to ascertain the efficiency of PFO closure for secondary prevention of DCI. However, the study shows that PFO closure does not fully protect against DCI, emphasizing that the relationship between PFO and DCI is but an association. As such it is imperative that divers be counseled to ensure they understand the risks as well as the benefits of percutaneous PFO closure in their specific case.


Asunto(s)
Enfermedad de Descompresión/prevención & control , Buceo/efectos adversos , Foramen Oval Permeable/terapia , Prevención Secundaria/métodos , Dispositivo Oclusor Septal , Adolescente , Adulto , Anciano , Enfermedad de Descompresión/etiología , Femenino , Foramen Oval Permeable/complicaciones , Humanos , Masculino , Persona de Mediana Edad , Enfermedades Profesionales/etiología , Enfermedades Profesionales/prevención & control , Implantación de Prótesis/efectos adversos , Implantación de Prótesis/métodos , Recreación , Recurrencia , Estudios Retrospectivos , Volver al Deporte/estadística & datos numéricos , Prevención Secundaria/instrumentación , Dispositivo Oclusor Septal/efectos adversos , Encuestas y Cuestionarios , Insuficiencia del Tratamiento , Adulto Joven
3.
J Emerg Med ; 42(6): 655-8, 2012 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-19500935

RESUMEN

BACKGROUND: Ecstasy is a popular drug among young adults. It is often thought to be safe. The dose of methylenedioxymethamphetamine (MDMA) in a tablet of Ecstasy varies greatly, and there is also a difference in individual response to a dose of MDMA. OBJECTIVES: To increase the awareness of potential mortality in MDMA use. CASE REPORT: We report the case of a patient with a lethal intoxication after pure MDMA intoxication. The serum toxicology screening showed an elevated level of MDMA (1.5 mg/L) but no other amphetamines or other drugs. CONCLUSIONS: The cause of death was a rapidly evolving hyperkalemia due to rhabdomyolysis. There is still a need to educate the public about the dangers of this so-called "safe" party drug.


Asunto(s)
Alucinógenos/envenenamiento , N-Metil-3,4-metilenodioxianfetamina/envenenamiento , Resultado Fatal , Humanos , Hiperpotasemia/etiología , Masculino , Rabdomiólisis/inducido químicamente , Adulto Joven
4.
J Cardiothorac Vasc Anesth ; 22(5): 699-705, 2008 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-18922426

RESUMEN

OBJECTIVE: To evaluate the effects of 2 different administration modalities of levosimendan (start before cardiopulmonary bypass [CPB] and at the end of CPB) compared with a standard treatment with milrinone started at the end of CPB in cardiac surgery patients with a preoperative ejection fraction <30%. DESIGN: A prospective study. SETTING: A university hospital. PARTICIPANTS: Sixty patients undergoing elective cardiac surgery with CPB. INTERVENTIONS: Patients were randomly assigned to 3 different treatment options for weaning from CPB after cardiac surgery. Group A received milrinone, 0.5 microg/kg/min, after the release of the aortic cross-clamp; group B received levosimendan, 0.1 microg/kg/min, after the induction of anesthesia; and in group C, levosimendan, 0.1 microg/kg/min, was started immediately after the release of the aortic cross-clamp. In all patients, additional dobutamine, 5 microg/kg/min, was initiated after the release of the aortic cross-clamp. Norepinephrine maintained mean arterial pressure constant. MEASUREMENTS AND MAIN RESULTS: Stroke volume after surgery was initially higher than at baseline in all groups and highest in group B. Stroke volume declined 12 hours after surgery in group A but not in groups B and C (p < 0.05 between groups), despite similar filling pressures. Four patients in group A, none in group B, and 1 in group C died within 30 days of surgery. Postoperative atrial fibrillation was observed in 10 patients in group A, 7 patients in group C, and only 1 in group B (p < 0.01). No differences were observed in postoperative troponin I release among groups. CONCLUSION: In the conditions of the present study, starting the levosimendan treatment before CPB was associated with a higher initial postoperative stroke volume and a lower incidence of postoperative atrial fibrillation, but had no effect on the extent of postoperative troponin I release.


Asunto(s)
Procedimientos Quirúrgicos Cardíacos , Cardiotónicos/administración & dosificación , Hidrazonas/administración & dosificación , Piridazinas/administración & dosificación , Anciano , Puente Cardiopulmonar , Femenino , Humanos , Masculino , Persona de Mediana Edad , Milrinona/uso terapéutico , Estudios Prospectivos , Simendán , Volumen Sistólico/efectos de los fármacos , Troponina I/sangre
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...